3/ #HIVinFocus

International guidelines recommend implementing the #Reprievestudy findings with different thresholds of #CVD risk statin therapy.

Australian guidance most closely aligns with the EACS recommendation.

A/Prof Janine Trevillyan from #AustinHealth describes the challenges of applying the #REPRIEVEstudy in Australia; we don’t have pitavastatin and use different risk calculators. #IDsky #HIVsky

Atorva- and rosuvastatin reduce surrogates of CVD risk, though choosing ideal biomarker can be challenging.

6/ #REPRIEVEstudy also highlighted that #CVD risk calculators tend to overestimate CVD risk in developing countries, but underestimate risk in women.

5/ #REPRIEVEstudy showed that statins were safe (pitavastatin was chosen because it doesn’t interact with PIs), with a non-sig trend towards incident #diabetes, though glycaemic control was curiously unchanged.

4/ #REPRIEVEstudy demonstrated definitively that statins reduce CVD risk in people with #HIV 35% with low to moderate #ASCVD risk at baseline.

3/ mechanistically statins reduce CVD risk through several mechanisms; LDL lowering, plaque stabilization, dampening inflammation. Interestingly #REPRIEVEstudy proteomic analysis suggested PCOLCE may be important in pitavastatin impact on collagen deposition.